GMP-Compliant Production of Human Placenta-Derived Mesenchymal Stem Cells

Hamid Reza Aghayan¹, Moloud Payab², Fereshteh Mohamadi-Jahani³, Seyed Sajjad Aghayan⁴, Bagher Larijani⁵, Babak Arjmand^{6

7}

Affiliations

¹ Cell Therapy and Regenerative Medicine Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
² Obesity and Eating Habits Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
³ Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
⁴ Cell-Based Therapies Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
⁵ Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
⁶ Cell Therapy and Regenerative Medicine Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. barjmand@sina.tums.ac.ir.
⁷ Metabolomics and Genomics Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. barjmand@sina.tums.ac.ir.

PMID: 32504292
DOI: 10.1007/7651_2020_282

GMP-Compliant Production of Human Placenta-Derived Mesenchymal Stem Cells

Hamid Reza Aghayan et al. Methods Mol Biol. 2021.

. 2021:2286:213-225.

doi: 10.1007/7651_2020_282.

Authors

Hamid Reza Aghayan¹, Moloud Payab², Fereshteh Mohamadi-Jahani³, Seyed Sajjad Aghayan⁴, Bagher Larijani⁵, Babak Arjmand^{6

7}

Affiliations

¹ Cell Therapy and Regenerative Medicine Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
² Obesity and Eating Habits Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
³ Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
⁴ Cell-Based Therapies Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
⁵ Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
⁶ Cell Therapy and Regenerative Medicine Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. barjmand@sina.tums.ac.ir.
⁷ Metabolomics and Genomics Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. barjmand@sina.tums.ac.ir.

PMID: 32504292
DOI: 10.1007/7651_2020_282

Abstract

Mesenchymal stem cells are one of the most attractive sources for stem cell research and therapy. Their safety and efficacy have been demonstrated in many clinical trials. Because of their low immunogenicity and immunomodulatory properties, allogenic MSCs have been transplanted in different clinical studies. MSCs could be in different adult- and fetal-derived tissues including pregnancy products. Placenta-derived mesenchymal stem cells (PLMSCs) that can be harvested without using any invasive procedures from a discarding tissue are one of the important types of mesenchymal stem cells for therapeutic applications. Stem cell manufacturing for therapeutic applications should be in compliance with the basic principles of good manufacturing practice (GMP). Herein, the current chapter is to describe GMP-compliant production of human PLMSCs, which are suitable for clinical applications.

Keywords: Cell culture; Cell therapy; Clinical application; GMP; Mesenchymal stem cells; Placenta.

PubMed Disclaimer

Cited by

Human-Induced Pluripotent Stem Cell‒Derived Keratinocytes, as Therapeutic Option in Vitiligo.
Arjmand B, Bahrami-Vahdat E, Alavi-Moghadam S, Arjmand R, Rezaei-Tavirani M, Namazi N, Larijani B. Arjmand B, et al. Methods Mol Biol. 2024;2849:185-202. doi: 10.1007/7651_2023_510. Methods Mol Biol. 2024. PMID: 38189899
Mesenchymal Stem Cells in Burn Wound Management.
Surowiecka A, Chrapusta A, Klimeczek-Chrapusta M, Korzeniowski T, Drukała J, Strużyna J. Surowiecka A, et al. Int J Mol Sci. 2022 Dec 5;23(23):15339. doi: 10.3390/ijms232315339. Int J Mol Sci. 2022. PMID: 36499664 Free PMC article. Review.
Chitosan based extruded nanofibrous bioscaffold for local delivery of mesenchymal stem cells to improve diabetic wound healing.
Abdollahi A, Aghayan HR, Mousivand Z, Motasadizadeh H, Maghsoudian S, Abdorashidi M, Ostad SN, Larijani B, Raoufi M, Javar HA. Abdollahi A, et al. Stem Cell Res Ther. 2024 Aug 15;15(1):262. doi: 10.1186/s13287-024-03772-7. Stem Cell Res Ther. 2024. PMID: 39148112 Free PMC article.
Standardized GMP-Compliant Scalable 3D-Bioprocessing of Epidermal Stem Cells for Diabetic Foot Ulcers.
Adibi H, Arjmand B, Aghayan HR, Bahrami-Vahdat E, Alavi-Moghadam S, Rezaei-Tavirani M, Arjmand R, Namazi N, Larijani B. Adibi H, et al. Methods Mol Biol. 2024;2849:173-183. doi: 10.1007/7651_2024_514. Methods Mol Biol. 2024. PMID: 38376750
Human placenta-derived mesenchymal stem cells transplantation in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 (phase I clinical trial): safety profile assessment.
Aghayan HR, Salimian F, Abedini A, Fattah Ghazi S, Yunesian M, Alavi-Moghadam S, Makarem J, Majidzadeh-A K, Hatamkhani A, Moghri M, Danesh A, Haddad-Marandi MR, Sanati H, Abbasvandi F, Arjmand B, Azimi P, Ghavamzadeh A, Sarrami-Forooshani R. Aghayan HR, et al. Stem Cell Res Ther. 2022 Jul 28;13(1):365. doi: 10.1186/s13287-022-02953-6. Stem Cell Res Ther. 2022. PMID: 35902979 Free PMC article. Clinical Trial.

See all "Cited by" articles

References

1. Ayala-Cuellar AP, Kang J-H, Jeung E-B et al (2019) Roles of mesenchymal stem cells in tissue regeneration and immunomodulation. Biomol Ther (Seoul) 27(1):25–33 - DOI
1. Goodarzi P, Alavi-Moghadam S, Payab M et al (2019) Metabolomics analysis of mesenchymal stem cells. Int J Mol Cell Med 8(Suppl 1):30–40
1. Soleimani M, Aghayan HR, Goodarzi P et al (2016) Stem cell therapy–approach for multiple sclerosis treatment. Arch Neurosci 3(1): e21564
1. Arjmand B, Tirdad R, Saki Malehi A et al (2018) Stem cell therapy for multiple sclerosis. Cochrane Database Syst Rev 2018(6):CD013049 - PMC
1. Goodarzi P, Aghayan HR, Larijani B et al (2015) Stem cell-based approach for the treatment of Parkinson’s disease. Med J Islam Repub Iran 29:168 - PubMed - PMC

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Springer

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

GMP-Compliant Production of Human Placenta-Derived Mesenchymal Stem Cells

Affiliations

GMP-Compliant Production of Human Placenta-Derived Mesenchymal Stem Cells

Authors

Affiliations

Abstract

Similar articles

Cited by

References

MeSH terms

LinkOut - more resources

Full Text Sources

Abstract

Similar articles

Cited by

References

MeSH terms

Related information

LinkOut - more resources

Full Text Sources